{Reference Type}: Journal Article
{Title}: Oral Pre-malignancy: An Update on Novel Therapeutic Approaches.
{Author}: Naara S;Andrews C;Sikora A;Williams M;Chambers M;Myers J;Amit M;
{Journal}: Curr Oncol Rep
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 12
{Factor}: 5.945
{DOI}: 10.1007/s11912-024-01562-1
{Abstract}: <B>OBJECTIVE: </B>This review aims to provide a comprehensive overview of the current advances in managing and preventing progression of oral potentially malignant disorders (OPMDs), focusing on their histological and clinicopathological features, and management.<BR><B>RESULTS: </B>Recent studies, including a multicenter cross-sectional study, have identified oral leukoplakia as the most prevalent form of OPMD, comprising over half of the cases examined. Advances in histological grading, specifically the World Health Organization's three-tier system (mild, moderate, and severe dysplasia), have significantly enhanced the accuracy of risk assessment for malignant transformation. Additionally, treatments such as surgical interventions, photodynamic therapy, and chemopreventive and molecularly targeted agents are being evaluated for their safety and efficacy as well as, immune checkpoint inhibitors being evaluated as potential preventive strategies to halt the progression of OPMDs. The management of OPMDs remains challenging due to the lack of standardized screening protocols and varied clinical management approaches. Despite this, recent advancements in diagnostic grading and therapeutic interventions provide a framework for improved treatment outcomes. Continued research into the molecular and cellular mechanisms driving development and progression of OPMDs and innovative treatment trials are essential to optimize strategies that prevent malignant progression and thereby reduce the global health burden of oral cancer.